Deep methodology knowledge for network meta-analysis including transitivity, consistency assessment, treatment rankings, and model selection. Use when conducting or reviewing NMA.
Scanned 6/5/2026
Install to Claude Code
npx -y skills add choxos/BiostatAgent --skill nma-methodology --agent claude-codeInstalls into .claude/skills of the current project.
Are you the author of Nma Methodology?
Add the live security badge to your README — it updates automatically with every re-scan.
[](https://www.skillsdirectory.com/skills/choxos-nma-methodology)More formats (shields.io, HTML) on the badges page.
---
name: nma-methodology
description: Deep methodology knowledge for network meta-analysis including transitivity, consistency assessment, treatment rankings, and model selection. Use when conducting or reviewing NMA.
---
# Network Meta-Analysis Methodology
Comprehensive methodological guidance for conducting rigorous network meta-analysis following NICE DSU and PRISMA-NMA guidelines.
## When to Use This Skill
- Planning a network meta-analysis
- Assessing transitivity and consistency
- Interpreting treatment rankings
- Choosing between frequentist and Bayesian NMA
- Designing NMA sensitivity analyses
- Reviewing NMA code or results
## Fundamental Assumptions
### 1. Transitivity Assumption
**Definition**: If we can estimate A vs B directly and B vs C directly, we can estimate A vs C indirectly, provided the studies are sufficiently similar.
**Requirements**:
- Studies comparing different treatments should be similar enough to have been included in the same RCT
- Effect modifiers should be balanced across comparisons
- No important differences in study-level characteristics
**Assessment**:
```
For each comparison in network, check:
├── Population similarity
│ - Age, sex, disease severity
│ - Biomarker status, prior treatments
├── Outcome definitions
│ - Same definition of response/event
│ - Same time point of assessment
├── Treatment definitions
│ - Dose, duration, route
│ - Concomitant medications
└── Study design
- Randomization, blinding
- Follow-up duration
```
**Presenting Transitivity Assessment**:
- Create table of study characteristics by comparison
- Highlight any systematic differences
- Use forest plots stratified by comparison
### 2. Consistency Assumption
**Definition**: Direct and indirect evidence for the same comparison should agree (within random variability).
**Relation to Transitivity**:
- Transitivity is untestable (conceptual)
- Consistency is testable (statistical)
- Consistency violations suggest transitivity violations
## Consistency Assessment
### Global Consistency Tests
#### Design-by-Treatment Interaction
```r
# netmeta
decomp.design(nma_result)
# Tests overall consistency across network
# Q statistic partitioned into within-design and between-design
```
#### Q Statistic Decomposition
- Q_total = Q_heterogeneity + Q_inconsistency
- Test Q_inconsistency against chi-square distribution
### Local Consistency: Node-Splitting
```r
# netmeta
netsplit(nma_result)
# gemtc
nodesplit_model <- mtc.nodesplit(network)
```
**Interpretation**:
| Direct vs Indirect | Conclusion |
|-------------------|------------|
| Similar (p > 0.05) | No evidence of inconsistency |
| Different (p < 0.05) | Possible inconsistency - investigate |
**Caution**: Multiple testing - expect some false positives.
### Net Heat Plot
```r
netheat(nma_result)
# Visual display of inconsistency
# Red: high inconsistency contribution
# Blue: low inconsistency
```
### What to Do with Inconsistency
1. **Check data** - errors in data entry
2. **Investigate sources** - which comparisons differ
3. **Explore heterogeneity** - meta-regression on potential modifiers
4. **Consider splitting network** - if clinical rationale exists
5. **Report transparently** - don't hide inconsistency
6. **Use inconsistency model** - as sensitivity analysis
## Treatment Rankings
### Frequentist (netmeta)
#### P-scores
```r
netrank(nma_result, small.values = "bad")
# P-score: probability of being better than average treatment
# Ranges 0-1
# NOT probability of being best
```
### Bayesian (gemtc)
#### SUCRA (Surface Under Cumulative Ranking Curve)
```r
sucra(mtc_result)
# Similar interpretation to P-score
# Based on cumulative ranking probabilities
```
#### Probability of Being Best
```r
rank.probability(mtc_result)
# Full ranking probability matrix
# Prob_best = P(rank = 1)
```
### Interpretation Cautions
**Critical**: Rankings are uncertain - always present with uncertainty measures.
```
Problems with rankings:
├── Small differences → different rankings
├── Wide credible intervals often ignored
├── Multiple treatments may be effectively tied
├── Rankings don't consider clinical relevance
└── "Best" might have limited evidence
```
**Best Practice**:
- Report ranking probabilities, not just point ranks
- Show cumulative ranking plots
- Consider clustering treatments by effect
- Discuss clinical significance alongside statistical
## Model Selection
### Fixed vs Random Effects
| Factor | Fixed-Effect | Random-Effects |
|--------|-------------|----------------|
| Studies similar | ✓ | ✓ |
| Studies different | ✗ | ✓ |
| Few studies per comparison | Consider | Default |
| Inference goal | Included studies | Broader population |
### Bayesian Prior Selection
#### Treatment Effects
```r
prior_trt = normal(0, sd)
# sd should be large enough to be weakly informative
# Consider scale of effect measure (log OR ~2-3 is large)
```
#### Heterogeneity (τ)
```r
prior_het = half_normal(scale)
# Scale depends on expected heterogeneity
# Turner et al. informative priors available
```
### Model Comparison
#### DIC (Deviance Information Criterion)
```r
# Lower is better
# Difference of ~3-5 is meaningful
dic(model1)
dic(model2)
```
#### Residual Deviance
- Compare to number of data points
- Should be close if model fits well
## Network Geometry
### Key Considerations
```
Network Structure Assessment:
├── Connectivity
│ - All treatments connected (directly or indirectly)?
│ - Star network? (single common comparator)
│ - Well-connected?
├── Evidence Distribution
│ - Some comparisons well-informed, others sparse?
│ - Imbalanced networks problematic
├── Multi-arm Trials
│ - Must account for correlations
│ - Contribution to network
└── Placebo/Active Control
- Consider clinical relevance of network anchor
```
### Contribution Matrix
```r
# netmeta
netcontrib(nma_result)
# Shows % contribution of each direct comparison to each estimate
```
### Network Graph
```r
netgraph(nma_result,
plastic = FALSE,
thickness = "number.of.studies",
multiarm = TRUE,
points = TRUE)
```
## Reporting Checklist (PRISMA-NMA)
### Methods
- [ ] Network geometry description
- [ ] Transitivity assessment approach
- [ ] Effect measure and rationale
- [ ] Model choice (fixed/random, frequentist/Bayesian)
- [ ] Prior specifications (if Bayesian)
- [ ] Consistency assessment methods
- [ ] Ranking methods and interpretation
- [ ] Sensitivity analyses planned
### Results
- [ ] Network diagram
- [ ] Study characteristics table by comparison
- [ ] Pairwise MA results (for direct evidence)
- [ ] NMA results for all comparisons
- [ ] League table
- [ ] Consistency assessment results
- [ ] Treatment rankings with uncertainty
- [ ] Sensitivity analysis results
## Common Pitfalls
### 1. Ignoring Transitivity
- Must assess before running NMA
- Not just a formality - fundamental requirement
### 2. Over-interpreting Rankings
- "Treatment A ranked #1" without uncertainty
- Small differences may give different rankings
- Clinical relevance matters more than rank
### 3. Selective Consistency Reporting
- Report all node-split results
- Don't dismiss inconsistency findings
### 4. Multi-arm Trial Handling
- Must account for correlations
- Software handles this, but check it's done correctly
### 5. Sparse Networks
- Very uncertain indirect comparisons
- Consider if NMA is appropriate
## Quick Reference Code
### Frequentist (netmeta)
```r
library(netmeta)
# Fit NMA
nma <- netmeta(TE, seTE, treat1, treat2, studlab,
data = pairwise_data,
sm = "OR",
reference.group = "Placebo",
random = TRUE)
# Network graph
netgraph(nma, plastic = FALSE, multiarm = TRUE)
# Forest vs reference
forest(nma, reference.group = "Placebo")
# League table
netleague(nma)
# Consistency
netsplit(nma)
netheat(nma)
# Rankings
netrank(nma, small.values = "bad")
```
### Bayesian (gemtc)
```r
library(gemtc)
library(rjags)
# Create network
network <- mtc.network(data.ab = arm_data)
# Fit model
model <- mtc.model(network,
likelihood = "binom",
link = "logit",
linearModel = "random")
result <- mtc.run(model, n.adapt = 5000, n.iter = 50000)
# Check convergence
gelman.diag(result)
# Summary
summary(result)
# Rankings
rank.probability(result)
sucra(result)
# Node-splitting
nodesplit <- mtc.nodesplit(network)
ns_result <- mtc.run(nodesplit)
summary(ns_result)
```
## Resources
- NICE DSU TSD 2: https://www.sheffield.ac.uk/nice-dsu/tsds
- PRISMA-NMA: Hutton et al. 2015
- Dias et al. (2018): Network Meta-Analysis for Decision Making
- Salanti (2012): Ann Intern Med - Intro to NMA
Is this your skill, or is something wrong with this listing? Request removal or report an issue. Author removals are honored within 72 hours.
No comments yet. Be the first to comment!